Clinical Trials
166 trialsBevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
University of Oklahoma
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab
University of Wisconsin, Madison
HAITI
Gruppo Oncologico del Nord-Ovest
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
Mayo Clinic
BIS-Program
Gustave Roussy, Cancer Campus, Grand Paris
Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
Vall d'Hebron Institute of Oncology
LOST-B
University of Texas Southwestern Medical Center
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NuCana plc
SCCC-06319
University of Texas Southwestern Medical Center
Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases
University of Southern California
VB-111 in Surgically Accessible Recurrent/Progressive GBM
Dana-Farber Cancer Institute
Postoperative Chemotherapy in High-Grade Appendiceal Adenocarcinoma With Peritoneal Carcinomatosis
University of California, San Diego
Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer
Massachusetts General Hospital
ABE-LIVER
University Hospital, Grenoble
Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients
Fundación GECP
Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma
Indiana University
CLavSyn
Centre Hospitalier Universitaire de Besancon
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Atezolizumab and Bevacizumab in Combination With TACE for Patients With BCLC B HCC
Yale University
Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
Hoosier Cancer Research Network
Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral Therapy
M.D. Anderson Cancer Center
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
Alliance for Clinical Trials in Oncology
Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)
Beijing Sanbo Brain Hospital
A Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy
Columbia University
HIGH-LIGHT
Federation Francophone de Cancerologie Digestive
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
University of Miami
Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)
Hoosier Cancer Research Network
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
M.D. Anderson Cancer Center
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma
Georgetown University
Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib
Duke University
Chemotherapy & Bevacizumab for Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-Negative Stage II/III Breast Cancer
University of Nebraska
Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma
University of Nebraska
1st Line Treatment of Bevacizumab-Taxane vs Bevacizumab-Exemestane in Metastatic Breast Cancer
ARCAGY/ GINECO GROUP
A Study of Amifostine (Ethyol) in Patients With Colorectal Cancer
University of Cincinnati
Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors
University of California, San Francisco
Corticosteroids + Bevacizumab vs. Corticosteroids + Placebo (BEST) for Radionecrosis After Radiosurgery for Brain Metastases
Alliance for Clinical Trials in Oncology
Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
Big Ten Cancer Research Consortium
A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)
Wake Forest University Health Sciences
SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22
Weill Medical College of Cornell University
OLGA
Universitätsklinikum Hamburg-Eppendorf
TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma
University of Florida
ABCDE
Dana-Farber Cancer Institute
Combination of Cetuximab, Capecitabine, and Oxaliplatin With or Without Bevacizumab
Fox Chase Cancer Center
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
SCRI Development Innovations, LLC
Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma
SCRI Development Innovations, LLC
Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
SCRI Development Innovations, LLC
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
RTOG Foundation, Inc.